Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Geolix.ai Joins Airwallex to Show Why Ranking #1 on Google No Longer Puts a Brand in the AI Answer

September 13, 2026

Trump drops tariff on Irish whiskey while booze ban looms for Canada

September 13, 2026

Planner Bee Expands Insurance Comparison Platform Covering 29 Singapore Insurers

September 13, 2026

Carney’s investment summit to be met with protests

September 13, 2026

Carney, Macron to meet as talks of stronger Canada-EU relationship ramp up

September 13, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)
Press Release

A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)

By News RoomJanuary 6, 20263 Mins Read
A Race Against Blindness Awards Additional .1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)
Share
Facebook Twitter LinkedIn Pinterest Email

GILBERT, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) — A Race Against Blindness, the Arizona-based 501(c)(3) nonprofit founded by Dr. Stephen Johnston and Kristina Johnston, today announced  $1.1 million in new grant funding to Axovia Therapeutics, closing a critical funding gap needed for the launch of the AXV-101 clinical trial, an investigational therapy aimed at treating vision loss associated with Bardet-Biedl Syndrome 1 (BBS1). This latest funding brings A Race Against Blindness’s total commitment for AXV-101 to $5.1 million.

The AXV-101 clinical trial received Clinical Trial Application (CTA) clearance during the third quarter of 2025. Despite this regulatory milestone, the trial could not move forward due to a remaining funding gap. The newly announced $1.1 million grant closes that gap, providing the vital funds needed to initiate the trial, which is now expected to begin in early 2026.

“This funding is a crucial milestone in bringing this investigational therapy into the clinic in the coming months,” said Prof. Phil Beales, Chief Executive Officer and Co-Founder of Axovia Therapeutics. “Our planned clinical trial is a first-in-human open-label dose-escalation trial, and as such, we’re moving forward with both urgency and care. We know how much uncertainty families face when they hear this diagnosis. Our goal is simple but powerful: to carefully explore whether this gene therapy can stop retinal degeneration, and, in time, change what it means to live with BBS1-related vision loss.”

A Race Against Blindness has played a central role in funding the advancement of AXV-101 from preclinical development through Clinical Trial Application (CTA) clearance, exemplifying its mission-driven approach to accelerating therapies for rare pediatric eye diseases.

“This commitment reflects our belief that promising therapies should not stall at the threshold of human trials due to lack of funding,” said Stephen Johnston, MD, MBA, Co-Founder of A Race Against Blindness. “This has been a deeply personal mission over the last 3 years, and to now be at this milestone leaves me full of gratitude and hope. The generosity of our supporters is both humbling and a beacon of light for what can be accomplished when people come together around a cause.”

About A Race Against Blindness

A Race Against Blindness is a family-run nonprofit founded by Stephen and Kristina Johnston after learning that their son has Retinitis Pigmentosa caused by Bardet-Biedl Syndrome, a rare condition leading to progressive vision loss in children. Their family has transformed a personal diagnosis into a mission to accelerate treatments for blinding diseases. Established to address the critical gap that often prevents promising vision therapies from reaching patients, A Race Against Blindness provides targeted, milestone-driven funding to move high-impact programs from the laboratory into human clinical trials.

Contact:

Dr. Stephen Johnston

Co-Founder & President

A Race Against Blindness

Email: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7487533c-7966-4edf-a94c-662278b9a14d

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Geolix.ai Joins Airwallex to Show Why Ranking #1 on Google No Longer Puts a Brand in the AI Answer

Planner Bee Expands Insurance Comparison Platform Covering 29 Singapore Insurers

Apeing Presale Surpasses $80,000 as Stage 3 Progresses Toward Scheduled Stage 4 Launch

Apeing Opens Stage 3 of $APEING Presale at $0.0004 as Project Advances Its 33-Stage Token Sale

Apeing Presale Surpasses $80,000 in Contributions as Stage 4 Launch Approaches

Crypto Price Today Highlights Solana Momentum as Apeing’s New Crypto Presale Stage 3 Almost Sold Out

JD.com’s 7Fresh Kitchen: “Chef Transformer” is coming!

REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

Building Global Trust in the AI Search Era: DigiMentumPR Explores the Future of PR for Technology Brands

Editors Picks

Trump drops tariff on Irish whiskey while booze ban looms for Canada

September 13, 2026

Planner Bee Expands Insurance Comparison Platform Covering 29 Singapore Insurers

September 13, 2026

Carney’s investment summit to be met with protests

September 13, 2026

Carney, Macron to meet as talks of stronger Canada-EU relationship ramp up

September 13, 2026

Latest News

Apple is reportedly working on iPhone game controllers

September 13, 2026

Saskatoon rally for the unhoused calls for action on forced displacement

September 13, 2026

Celine Dion kicks off 1st show in 6 years at Paris residency: ‘I missed this’

September 13, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version